Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).